Scrip
New US labelling for Erbitux and Vectibix recommends against their use for large subset of colorectal cancer patients
20 July 2009
Malini Guha
The US labelling of
Lilly (ImClone)/
Bristol-Myers Squibb 's Erbitux (cetuximab) and
Amgen's Vectibix (panitumumab) have been revised to highlight the fact that the EGFR-targeted drugs are not recommended for use in the approximately 40% of metastatic colorectal cancer (mCRC) patients who have a...
Please Login to read the full article.
20 July 2009
Malini Guha
Please Login to read the full article.
RELATED CONTENT
NEWS
- Vectibix clears PFS but survival hurdle still awaits in colorectal cancer
- Mixed Phase III results for Erbitux in first-line colorectal cancer
- Amgen's Vectibix fails to show survival benefit in pivotal first-line trial in colorectal cancer
- Vectibix recommended for colorectal cancer in Japan
ANALYSIS
Other Informa Analysis
FEATURES
Other Informa Features
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
